Tests PF-07328948 pill in adults with heart failure
Tests a new study pill against a placebo in adults with heart failure.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Key facts
- Where
- Ponce, Puerto RicoSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT06991257, who can take part
Where in Puerto Rico
- Research and Cardiovascular CorpPonce, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06991257EU 2024-518438-94-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).Read full original descriptionShow less
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Inclusion: aged 18 years to < 80 years; clinically confirmed to have a diagnosis of heart failure for at least 3 months; New York Heart Association Class II-IV symptoms; left ventricular ejection fraction greater than 40%; Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85; Six-minute walking distance greater than 75 meters.
Exclusion: Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor; Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor; Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body; History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes.
This study is seeking participants who are:.